{"name":"Universiteit Antwerpen","slug":"universiteit-antwerpen","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"mRNA-1273 100µg","genericName":"mRNA-1273 100µg","slug":"mrna-1273-100-g","indication":"Other","status":"marketed"},{"name":"Lactobacillus casei Shirota","genericName":"Lactobacillus casei Shirota","slug":"lactobacillus-casei-shirota","indication":"Other","status":"marketed"},{"name":"Pravastatin-Pravasine","genericName":"Pravastatin-Pravasine","slug":"pravastatin-pravasine","indication":"Other","status":"phase_1"},{"name":"Quinvaxem","genericName":"Quinvaxem","slug":"quinvaxem","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"mRNA-1273 100µg","genericName":"mRNA-1273 100µg","slug":"mrna-1273-100-g","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lactobacillus casei Shirota","genericName":"Lactobacillus casei Shirota","slug":"lactobacillus-casei-shirota","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pravastatin-Pravasine","genericName":"Pravastatin-Pravasine","slug":"pravastatin-pravasine","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Quinvaxem","genericName":"Quinvaxem","slug":"quinvaxem","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPNVUycW1weTBvQklFQXhnb2tHSTl6cnh1NVBvdkI2bnRsNnF6NmJDVHljczdSVXpIaUE5cW92SjJuWUxoa0lRZHBqVDRyMHVDaGs4ZXZwRUtEdE5qcFJ3bnRQbVdNUnhiZlBlV1ZLbW5MWVN5XzVualVIU2tuYzBBRnZGdkNybUN6cWZReFFDM19LRE5jUmJnZW9B?oc=5","date":"2025-10-24","type":"trial","source":"Frontiers","summary":"Implementation of Medication Review Type 2a in Community Pharmacies: A Longitudinal Survey Study - Frontiers","headline":"Implementation of Medication Review Type 2a in Community Pharmacies: A Longitudinal Survey Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNZWVid2swRW01X205MTRtdUNQNzZxck1SdmlROE9zS1NRb1hXWEk2LTBpUHFBUU1FZFFHams5dXMxZ0JMamVYWjVoSGFIMndRQTdhUndlMGp1YVVlenRqRndCcmpsRUZ3ZVBPTzhvQ01LZEdmX1NfZTd2cndVWnpfZEgzYUxROW9ZcnkwLXRSRkdobi1T?oc=5","date":"2023-10-03","type":"pipeline","source":"Frontiers","summary":"Key elements in the quality assessment of a type 3 medication review - Frontiers","headline":"Key elements in the quality assessment of a type 3 medication review","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":3,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}